Cyclopharm Limited (AU:CYC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cyclopharm Limited has announced a significant partnership with the US Veterans Administration, securing an interim agreement to supply Technegas, a diagnostic product for lung diseases, to 120 VA hospitals. This deal is a precursor to broader inclusion in the US Federal Supply Schedule, expected to enhance care for conditions such as COPD and pulmonary fibrosis in veterans. Concurrently, Cyclopharm has also received its first Technegas order from the US Department of Defense, marking a strategic advancement in the company’s expansion within the largest nuclear medicine market.
For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.